Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Toshiyuki Yoneda is active.

Publication


Featured researches published by Toshiyuki Yoneda.


Calcified Tissue International | 1982

Release of the lymphokine osteoclast activating factor requires cyclic AMP accumulation

Toshiyuki Yoneda; Gregory R. Mundy

SummaryThe bone resorbing lymphokine osteoclast activating factor (OAF) is released by lymphocytes activated by phytohemagglutinin (PHA). In this study we have found that release of OAF by activated lymphocytes is dependent on cyclic AMP (cAMP). OAF release is preceded by cAMP accumulation in the lymphocytes, and when cAMP accumulation is impaired by treatment of activated leukocytes with indomethacin, OAF is not released. OAF release in these cultures is restored by the addition of agents that mimic or increase lymphocyte cAMP content by different mechanisms. When activated purified lymphocytes that do not release OAF by themselves were cultured with these agents, OAF appeared in the culture media. These results suggest that cyclic AMP accumulation in lymphocytes is required for OAF to be released after activation.


Archive | 1996

Composition to ameliorate osteolysis and metastasis

Gregory R. Mundy; Toshiyuki Yoneda; Theresa A. Guise


Archive | 1996

COMPOSITION TO INHIBIT OSTEOLYSIS AND METASTASIS

Theresa A. Guise; Gregory R. Mundy; Toshiyuki Yoneda


Archive | 2013

METHOD BY USE OF INTEGRIN ANTAGONIST FOR TREATMENT OF MULTIPLE MYELOMA AND MYELOMA INDUCEMENT BONE RESORPTION

Gregory R. Mundy; マンディ,グレゴリ−・アール; Toshiyuki Yoneda; 俊之 米田


Archive | 2013

osteoclast-stimulating activity 1-integrin enhances production of β 4 α VCAM-1 and cell contact between marrow stromal cells and myeloma cells via - Cell

Toshiyuki Yoneda; Toshimi Michigami; Nobuaki Shimizu; Paul J. Williams; Maria Niewolna; Sarah L. Dallas


Archive | 2010

myeloma and associated osteoclastic osteolysis Anti-{alpha}4 integrin antibody suppresses the development of multiple

Gregory R. Mundy; Toshiyuki Yoneda; Yoshihisa Mori; Nobuaki Shimizu; Mark Dallas; Maryla Niewolna; Beryl Story; Paul J. Williams


Archive | 1999

Verfahren zur behandlung von multiplem myelom und von myelom- induzierter knochenresorption mit antagonisten der integrin-/rezeptorbindung Process for the treatment of multiple myeloma and myeloma-induced bone resorption with antagonists of the integrin / receptor binding

Gregory R. Mundy; Toshiyuki Yoneda


Archive | 1999

Methods of treating multiple myeloma and myeloma-induced bone resorption using receptor antagonists / integrin junction.

Gregory R. Mundy; Toshiyuki Yoneda


Archive | 1999

Procédés de traitement de myélome multiple et de résorption osseuse liée au myélome utilisant des antagonistes d'intégrine

Gregory R. Mundy; Toshiyuki Yoneda


Archive | 1999

Traitement du myelome multiple et de la resorption osseuse associee au moyen d'antagonistes de l'interaction integrine / recepteur

Gregory R. Mundy; Toshiyuki Yoneda

Collaboration


Dive into the Toshiyuki Yoneda's collaboration.

Top Co-Authors

Avatar

Gregory R. Mundy

University of Texas at Austin

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Paul J. Williams

University of Texas Health Science Center at San Antonio

View shared research outputs
Top Co-Authors

Avatar

Beryl Story

University of Texas Health Science Center at San Antonio

View shared research outputs
Top Co-Authors

Avatar

Maria Niewolna

University of Texas Health Science Center at San Antonio

View shared research outputs
Top Co-Authors

Avatar

Mark Dallas

University of Missouri–Kansas City

View shared research outputs
Top Co-Authors

Avatar

Sarah L. Dallas

University of Texas Health Science Center at San Antonio

View shared research outputs
Top Co-Authors

Avatar

Toshimi Michigami

University of Texas Health Science Center at San Antonio

View shared research outputs
Researchain Logo
Decentralizing Knowledge